経口血糖降下薬の世界市場レポート 2025年

経口血糖降下薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.2％で736億9,000万米ドルに成長します。予測期間においては、併用療法に対する需要の高まり、政府のヘルスケア政策への支援、糖尿病治療への遠隔医療の導入拡大、糖尿病治療に対する研究開発投資の拡大、個別化治療アプローチへの重点化などが成長を牽引すると予想されます。この時期の主な動向としては、新規経口抗糖尿病薬の開発、合剤の創出、薬剤製剤技術の発展、薬剤の副作用軽減への取り組み、血糖モニタリングのためのデジタルヘルスツールの統合などが挙げられます。

2型糖尿病の有病率の増加は、経口血糖降下薬市場の成長を促進すると予想されます。2型糖尿病は、体内でインスリンの効きが悪くなり、血糖値が高くなる慢性代謝疾患です。2型糖尿病の増加は、身体活動を減らし、肥満やインスリン抵抗性を引き起こす、より座りがちなライフスタイルによるところが大きいです。経口血糖降下薬は、インスリン感受性の改善、インスリン産生の促進、グルコース吸収の抑制などのメカニズムにより血糖値を下げることで、2型糖尿病を管理するために使用されます。国際糖尿病連合（IDF）によると、2025年4月現在、世界中で5億8,900万人の20～79歳の成人が糖尿病を患っており、この数は2050年までに8億5,300万人に増加すると予測されています。この2型糖尿病罹患率の増加は、経口血糖降下薬の市場成長を促進すると予想されています。

経口血糖降下薬市場の主要企業は、2型糖尿病患者の血糖コントロールを強化するため、ジペプチジルペプチダーゼ-4（DPP-4）阻害薬などの先進的な治療オプションの開発に注力しています。DPP-4阻害薬は、インクレチンホルモンのレベルを上昇させ、インスリン産生を刺激して血糖値を下げる薬です。例えば、2022年6月、中国の製薬会社Gan &Lee Pharmaceuticals Co.Ltd.は、2型糖尿病を効果的に管理するための経口血糖降下薬であるシタグリプチンリン酸塩錠の承認を取得しました。この製品タイプはDPP-4酵素を阻害することで血糖値を調整するもので、ガン・アンド・リー製薬がジェネリック医薬品市場に参入したことを意味し、2型糖尿病管理により手頃な価格の選択肢を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の経口血糖降下薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の経口血糖降下薬市場：成長率分析
• 世界の経口血糖降下薬市場の実績：規模と成長, 2019-2024
• 世界の経口血糖降下薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の経口血糖降下薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の経口血糖降下薬市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• スルホニル尿素
• メトホルミン
• チアゾリジンジオン
• アルファグルコシダーゼ阻害剤
• 免疫療法
• 世界の経口血糖降下薬市場投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口錠
• 経口液
• 徐放性製剤
• 併用療法製剤
• 世界の経口血糖降下薬市場患者タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 2型糖尿病患者
• 糖尿病前症患者
• 肥満または過体重の患者
• 複数の合併症を持つ患者
• 世界の経口血糖降下薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 老人ホームと長期ケア施設
• 世界の経口血糖降下薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 世界の経口血糖降下薬市場：スルホニル尿素剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• グリピジド
• グリブリド
• グリメピリド
• クロルプロパミド
• トルブタミド
• 世界の経口血糖降下薬市場：メトホルミンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 即放性メトホルミン
• 徐放性メトホルミン（XR）
• メトホルミン併用
• 世界の経口血糖降下薬市場：チアゾリジンジオン（TZD）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ピオグリタゾン
• ロシグリタゾン
• 世界の経口血糖降下薬市場：α-グルコシダーゼ阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アカルボース
• ミグリトール
• ボグリボース
• 世界の経口血糖降下薬市場：免疫療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• テプリズマブ
• ミョウバン配合GAD（GAD-ミョウバン）
• ディアミド
• 抗CD3モノクローナル抗体

第7章 地域別・国別分析

• 世界の経口血糖降下薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の経口血糖降下薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 経口血糖降下薬市場：競合情勢
• 経口血糖降下薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Janssen Global Services LLC Overview, Products and Services, Strategy and Financial Analysis
  • Merck Sharp & Dohme Corp. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• AstraZeneca plc
• Novartis AG
• GSK plc
• Takeda Pharmaceuticals Limited
• Eli Lilly and Company
• Boehringer Ingelheim Ltd.
• Novo Nordisk A/S
• Astellas Pharma Inc.
• Laboratoires Servier
• Huadong Medicine Co. Ltd.
• Tonghua Dongbao Pharmaceutical Co. Ltd.
• Gan & Lee Pharmaceuticals Co. Ltd.
• Biocon Limited
• Wanbang Biopharmaceuticals Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 経口血糖降下薬市場2029：新たな機会を提供する国
• 経口血糖降下薬市場2029：新たな機会を提供するセグメント
• 経口血糖降下薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Oral hypoglycemic agents (OHAs) are medications taken orally to help reduce blood glucose (sugar) levels in individuals with type 2 diabetes mellitus. These medications work through different mechanisms, including increasing insulin secretion, enhancing insulin sensitivity, decreasing glucose absorption from the gut, or reducing glucose production by the liver. OHAs are typically prescribed when lifestyle changes, such as diet and exercise, are not enough to control blood sugar levels.

The primary types of oral hypoglycemic agents include sulfonylureas, metformin, thiazolidinediones, alpha-glucosidase inhibitors, and immunotherapy. Sulfonylureas are a class of oral hypoglycemic agents that stimulate the pancreas to release more insulin by targeting beta cells, which helps lower blood glucose levels in individuals with type 2 diabetes. These drugs are available in various forms, such as oral tablets, oral liquids, extended-release formulations, and combination therapy formulations. The patient groups include individuals with type 2 diabetes mellitus, pre-diabetic patients, obese or overweight individuals, and those with multiple comorbidities. They are distributed through various channels like hospital pharmacies, retail pharmacies, online pharmacies, and nursing homes or long-term care facilities. The main end users are hospitals and clinics.

The oral hypoglycemic agents market research report is one of a series of new reports from The Business Research Company that provides oral hypoglycemic agents market statistics, including the oral hypoglycemic agents industry global market size, regional shares, competitors with the oral hypoglycemic agents market share, detailed oral hypoglycemic agents market segments, market trends, and opportunities, and any further data you may need to thrive in the oral hypoglycemic agents industry. This oral hypoglycemic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oral hypoglycemic agents market size has grown strongly in recent years. It will grow from $57.04 billion in 2024 to $60.15 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historic period can be attributed to factors such as the increasing prevalence of type 2 diabetes, a rising geriatric population, greater awareness of diabetes management, expanded healthcare access in emerging markets, and a preference for oral therapies over injectable ones.

The oral hypoglycemic agents market size is expected to see strong growth in the next few years. It will grow to $73.69 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. In the forecast period, growth is expected to be driven by a rising demand for combination therapies, supportive government healthcare policies, increased adoption of telemedicine for diabetes care, greater investment in research and development for diabetes treatments, and a stronger focus on personalized treatment approaches. Key trends in this period include the development of novel oral antidiabetic drugs, the creation of fixed-dose combinations, advancements in drug formulation technologies, efforts to reduce drug side effects, and the integration of digital health tools for glucose monitoring.

The increasing prevalence of type 2 diabetes is expected to drive the growth of the oral hypoglycemic agents market. Type 2 diabetes is a chronic metabolic disorder where the body becomes ineffective in using insulin, resulting in high blood glucose levels. The rise in type 2 diabetes is largely due to more sedentary lifestyles, which reduce physical activity and contribute to obesity and insulin resistance. Oral hypoglycemic agents are used to manage type 2 diabetes by lowering blood glucose through mechanisms such as improving insulin sensitivity, stimulating insulin production, or reducing glucose absorption. According to the International Diabetes Federation (IDF), nearly 589 million adults aged 20-79 are living with diabetes worldwide as of April 2025, and this number is projected to rise to 853 million by 2050. This increasing incidence of type 2 diabetes is expected to drive market growth for oral hypoglycemic agents.

Leading companies in the oral hypoglycemic agents market are concentrating on developing advanced therapeutic options, including dipeptidyl peptidase-4 (DPP-4) inhibitors, to enhance blood sugar control for type 2 diabetes patients. DPP-4 inhibitors are medications that increase incretin hormone levels, stimulating insulin production to reduce blood sugar levels. For example, in June 2022, Gan & Lee Pharmaceuticals Co. Ltd., a China-based pharmaceutical company, received approval for Sitagliptin Phosphate tablets, an oral hypoglycemic medication designed to manage type 2 diabetes effectively. This product works by inhibiting the DPP-4 enzyme, helping regulate blood sugar levels, and marks Gan & Lee Pharmaceuticals' entry into the generic drug market, offering a more affordable option for managing type 2 diabetes.

In July 2024, F. Hoffmann-La Roche Ltd., a Swiss pharmaceutical company, acquired Carmot Therapeutics Inc. for \$2.7 billion. This acquisition allows Roche to strengthen its position in the obesity and diabetes treatment market by expanding its portfolio of incretin-based therapies. Carmot Therapeutics Inc., based in the US, specializes in developing incretin-based treatments for obesity, diabetes, and related metabolic conditions.

Major players in the oral hypoglycemic agents market are Pfizer Inc., Janssen Global Services LLC, Merck Sharp & Dohme Corp., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceuticals Limited, Eli Lilly and Company, Boehringer Ingelheim Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Laboratoires Servier, Huadong Medicine Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Gan & Lee Pharmaceuticals Co. Ltd., Biocon Limited, Wanbang Biopharmaceuticals Co. Ltd.

North America was the largest region in the oral hypoglycemic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oral hypoglycemic agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oral hypoglycemic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral hypoglycemic agents market consists of sales of DPP-4 inhibitors, alpha-glucosidase inhibitors, biguanides, and thiazolidinediones (TZDs). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Hypoglycemic Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral hypoglycemic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral hypoglycemic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral hypoglycemic agents market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Sulfonylureas; Metformin; Thiazolidinediones; Alpha-Glucosidase Inhibitors; Immunotherapy
• 2) By Administration Route: Oral Tablets; Oral Liquids; Extended-Release Formulations; Combination Therapy Formulations
• 3) By Patient Type: Type 2 Diabetes Mellitus Patients; Pre-diabetic Patients; Obese Or Overweight Patients; Patients with Multiple Comorbidities
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Nursing Homes and Long-Term Care Facilities
• 5) By End users: Hospitals; Clinics
• Subsegments:
• 1) By Sulfonylureas: Glipizide; Glyburide; Glimepiride; Chlorpropamide; Tolbutamide
• 2) By Metformin: Immediate-Release Metformin; Extended-Release Metformin (XR); Combination Metformin
• 3) By Thiazolidinediones (TZDs): Pioglitazone; Rosiglitazone
• 4) By Alpha-Glucosidase Inhibitors: Acarbose; Miglitol; Voglibose
• 5) By Immunotherapy: Teplizumab; Alum-Formulated GAD (GAD-Alum); Diamyd; Anti-CD3 Monoclonal Antibodies
• Companies Mentioned: Pfizer Inc.; Janssen Global Services LLC; Merck Sharp & Dohme Corp.; Bayer AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oral Hypoglycemic Agents Market Characteristics

3. Oral Hypoglycemic Agents Market Trends And Strategies

4. Oral Hypoglycemic Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Oral Hypoglycemic Agents Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oral Hypoglycemic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oral Hypoglycemic Agents Market Growth Rate Analysis
• 5.4. Global Oral Hypoglycemic Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oral Hypoglycemic Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oral Hypoglycemic Agents Total Addressable Market (TAM)

6. Oral Hypoglycemic Agents Market Segmentation

• 6.1. Global Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sulfonylureas
• Metformin
• Thiazolidinediones
• Alpha-Glucosidase Inhibitors
• Immunotherapy
• 6.2. Global Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets
• Oral Liquids
• Extended-Release Formulations
• Combination Therapy Formulations
• 6.3. Global Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 2 Diabetes Mellitus Patients
• Pre-Diabetic Patients
• Obese Or Overweight Patients
• Patients With Multiple Comorbidities
• 6.4. Global Oral Hypoglycemic Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Nursing Homes and Long-Term Care Facilities
• 6.5. Global Oral Hypoglycemic Agents Market, Segmentation By End users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• 6.6. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glipizide
• Glyburide
• Glimepiride
• Chlorpropamide
• Tolbutamide
• 6.7. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate-Release Metformin
• Extended-Release Metformin (XR)
• Combination Metformin
• 6.8. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Thiazolidinediones (TZDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pioglitazone
• Rosiglitazone
• 6.9. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acarbose
• Miglitol
• Voglibose
• 6.10. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Teplizumab
• Alum-Formulated GAD (GAD-Alum)
• Diamyd
• Anti-CD3 Monoclonal Antibodies

7. Oral Hypoglycemic Agents Market Regional And Country Analysis

• 7.1. Global Oral Hypoglycemic Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oral Hypoglycemic Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oral Hypoglycemic Agents Market

• 8.1. Asia-Pacific Oral Hypoglycemic Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oral Hypoglycemic Agents Market

• 9.1. China Oral Hypoglycemic Agents Market Overview
• 9.2. China Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oral Hypoglycemic Agents Market

• 10.1. India Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oral Hypoglycemic Agents Market

• 11.1. Japan Oral Hypoglycemic Agents Market Overview
• 11.2. Japan Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oral Hypoglycemic Agents Market

• 12.1. Australia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oral Hypoglycemic Agents Market

• 13.1. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oral Hypoglycemic Agents Market

• 14.1. South Korea Oral Hypoglycemic Agents Market Overview
• 14.2. South Korea Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oral Hypoglycemic Agents Market

• 15.1. Western Europe Oral Hypoglycemic Agents Market Overview
• 15.2. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oral Hypoglycemic Agents Market

• 16.1. UK Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oral Hypoglycemic Agents Market

• 17.1. Germany Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oral Hypoglycemic Agents Market

• 18.1. France Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oral Hypoglycemic Agents Market

• 19.1. Italy Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oral Hypoglycemic Agents Market

• 20.1. Spain Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oral Hypoglycemic Agents Market

• 21.1. Eastern Europe Oral Hypoglycemic Agents Market Overview
• 21.2. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oral Hypoglycemic Agents Market

• 22.1. Russia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oral Hypoglycemic Agents Market

• 23.1. North America Oral Hypoglycemic Agents Market Overview
• 23.2. North America Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oral Hypoglycemic Agents Market

• 24.1. USA Oral Hypoglycemic Agents Market Overview
• 24.2. USA Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oral Hypoglycemic Agents Market

• 25.1. Canada Oral Hypoglycemic Agents Market Overview
• 25.2. Canada Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oral Hypoglycemic Agents Market

• 26.1. South America Oral Hypoglycemic Agents Market Overview
• 26.2. South America Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oral Hypoglycemic Agents Market

• 27.1. Brazil Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oral Hypoglycemic Agents Market

• 28.1. Middle East Oral Hypoglycemic Agents Market Overview
• 28.2. Middle East Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oral Hypoglycemic Agents Market

• 29.1. Africa Oral Hypoglycemic Agents Market Overview
• 29.2. Africa Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oral Hypoglycemic Agents Market Competitive Landscape And Company Profiles

• 30.1. Oral Hypoglycemic Agents Market Competitive Landscape
• 30.2. Oral Hypoglycemic Agents Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Janssen Global Services LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck Sharp & Dohme Corp. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Oral Hypoglycemic Agents Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca plc
• 31.3. Novartis AG
• 31.4. GSK plc
• 31.5. Takeda Pharmaceuticals Limited
• 31.6. Eli Lilly and Company
• 31.7. Boehringer Ingelheim Ltd.
• 31.8. Novo Nordisk A/S
• 31.9. Astellas Pharma Inc.
• 31.10. Laboratoires Servier
• 31.11. Huadong Medicine Co. Ltd.
• 31.12. Tonghua Dongbao Pharmaceutical Co. Ltd.
• 31.13. Gan & Lee Pharmaceuticals Co. Ltd.
• 31.14. Biocon Limited
• 31.15. Wanbang Biopharmaceuticals Co. Ltd.

32. Global Oral Hypoglycemic Agents Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oral Hypoglycemic Agents Market

34. Recent Developments In The Oral Hypoglycemic Agents Market

35. Oral Hypoglycemic Agents Market High Potential Countries, Segments and Strategies

• 35.1 Oral Hypoglycemic Agents Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oral Hypoglycemic Agents Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oral Hypoglycemic Agents Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer